Health Catalyst

Medicaid Cuts Will Constrict Deals But Spur Efficiency

AnalystLowTarget

Not Invested

Community Contributor

Published

10 Aug 25

AnalystLowTarget's Fair Value

US$3.50

18.6% undervalued

04 Sep

US$2.85

-63.6%

You can edit this narrative until Aug 10 11:10 PM. Then, changes will post as Updates.

Author's Valuation

US$3.518.6% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$3.5

18.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.43%

Healthtech revenue growth rate

6.18%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

10.05%

Calculation

US$34.26m

Earnings '28

14.66x

PE Ratio '28

US$502.16m

Market Cap '28

US$502.16m

Market Cap '28

108.87m

No. shares '28

US$4.61

Share Price '28

US$4.61 Share Price '28

Discounted to 2025 @ 9.63% p.a.

US$3.50

Fair Value '25